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As a powerful phenotyping technology, metabolomics provides new opportunities in biomarker 
discovery through metabolome-wide association studies (MWAS) and the identification of metabolites 
having a regulatory effect in various biological processes. While mass spectrometry-based (MS) 
metabolomics assays are endowed with high throughput and sensitivity, MWAS are doomed to long-
term data acquisition generating an overtime-analytical signal drift that can hinder the uncovering of 
real biologically relevant changes. We developed “dbnorm”, a package in the R environment, which 
allows for an easy comparison of the model performance of advanced statistical tools commonly 
used in metabolomics to remove batch effects from large metabolomics datasets. “dbnorm” 
integrates advanced statistical tools to inspect the dataset structure not only at the macroscopic 
(sample batches) scale, but also at the microscopic (metabolic features) level. To compare the model 
performance on data correction, “dbnorm” assigns a score that help users identify the best fitting 
model for each dataset. In this study, we applied “dbnorm” to two large-scale metabolomics datasets 
as a proof of concept. We demonstrate that “dbnorm” allows for the accurate selection of the most 
appropriate statistical tool to efficiently remove the overtime signal drift and to focus on the relevant 
biological components of complex datasets.
Large datasets generated by metabolomics have become an essential source of information about molecular 
phenotypes in systems biology  studies1–4. As an intermediate molecular layer between genes and disease phe-
notypes, metabolite levels and the corresponding pattern of changes are strongly associated with the degree of 
perturbation of biological systems and rewired metabolic networks for a given  phenotype5–12.
Liquid chromatography-MS (LC–MS) is widely used in the study of the metabolome owing to the progressive 
improvement of its instrumental conditions in terms of its sensitivity and  selectivity13. However, LC–MS-based 
metabolomics assays suffer from inherent variations in the distribution of signal measurements and/or in its 
signal sensitivity and intensity driven by external  factors14. This signal drift is a major limitation of current data 
normalization in biomedical and clinical studies, resulting in unavoidable technical variations introduced during 
sample preparation and  analysis15. In particular, such a drift can significantly compromise the technical preci-
sion and signal stability in large-scale studies, where the data acquisition for several hundreds to thousands of 
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biological samples needs to be completed in different analytical blocks (i.e., batches) over several weeks or even 
 months15,16. In this case, the largest variance in the dataset may be assigned to the batch effects or experimental 
run order, thus hindering identification of the real biological differences and true functional signals, leading 
to data  misinterpretation15,17,18. Therefore, large metabolomics datasets need to be corrected for unwanted and 
within and between-batch, analytical variation to make the data comparable and to reveal biologically relevant 
 changes19–21.
Several methods have been developed for the batch correction of metabolomics datasets, but the choice is 
not  easy22. In most LC–MS-based metabolomics data processing workflows, signal intensity drift correction is 
performed using quality control (QC) samples. QC samples are aliquots of a QC pool, representative of the entire 
sample set. QC samples are injected within each batch to monitor the signal drift over time and to evaluate the 
system performance and data  quality23–25. However, in large-scale studies, the preparation of such QC samples 
may be difficult due to the large number of samples, whose handling would involve additional freeze–thaw cycles. 
According to the experimental design surrogate QC samples can be  applied23,26–29. In general, drift correction 
using QCs is based on the assumption that the same sources of variation apply to the metabolites present in both 
the biological samples and the QCs as their representative pools. In a majority of QC sample-based workflows, 
several commonly proposed algorithms are used for batch effect correction, such as feature-based correction 
 algorithms30, regression-based  models30,31, linear and nonlinear smoothing algorithms (e.g., lowess models)23,31–34, 
and classification- and regression-based models (i.e., random forest)35.
Models not based on QC samples mainly fall into two categories, matrix factorization (MF) and location-
scale (L/S)-based methods, leveraging genomics-based approaches. Both of these methods can directly remove 
batch effects from the subject  samples36. Initially, MF-based methods were developed to model the covariates in 
a differential analysis of the genomics  data37. To remove batch variance, MF approaches usually perform either 
singular value decomposition (SVD) or principal component analysis (PCA), and the batch effect must be associ-
ated with the first factor (or component) showing the highest possible  variance38. Some implementations of such 
an approach are independent component analysis (ICA) and  EigenMS36 . The major drawback of the MF-based 
model is that if no clear batch effect is captured in the first ranked components, then the data matrix remains 
unchanged 37. Location-scale (L/S)-based methods are the most straightforward. Various implementations of 
such categories have been proposed, such as the mean-centering, standardization and ratio-based  methods38 .
ComBat is also a function established in this category that uses the empirical Bayes methods (EB) framework 
for estimation of the L/S parameters that represent batch  effects18,39–42. ComBat has the flexibility to adjust the 
batch effect by integrating information on both batches and the biological covariates or just in the batches if 
the demography of the population is not  available10,15. This statistical approach is developed in the context of 
“parametric shrinkage adjustment”, in which the batch effect is removed in three steps: data standardization, 
batch effect estimation via empirical priors and batch effect removal using the adjusted  estimators42. Although 
it makes strong parametric estimation, ComBat has been recognized for its superior performance in adjusting 
of unwanted variation compared to several other  models39. Another statistical model that was originally devel-
oped for microarray data is ber, which removes batch effects by using linear fitting for both location and scale 
(L/S)  parameters43. Interestingly, this model showed a better performance in microarray data compared to the 
empirical Bayes  models43, but it was never tested on metabolomics data.
Although all of these approaches may be successfully applied to remove batch effects from metabolomics data-
sets, the selection of the most appropriate approach is dependent on the dataset structure and should be tested 
by the  users44. With this goal, here we describe “dbnorm”, a new package in the R environment, which aims to 
compare state-of-the-art statistical approaches for the removal of batch effects from metabolomics datasets. This 
package incorporates several tools for preprocessing large datasets and estimation of missing values. In addition, 
“dbnorm” includes two distinct statistical models for batch effect correction: ComBat, both the parametric and 
nonparametric versions), and ber, including its bagging version, as explained in detail in the Methods section. Of 
note, for each analyzed dataset, “dbnorm” generates diagnostic plots that help users visualize the structure of their 
data at both the sample level and the feature level. Moreover, “dbnorm” calculates a score value that allows users 
to easily choose the statistical correction model that best fits their data structure. This score, which is denoted 
by adjusted- R squared (adj-R2), ranges from 0 to 1 and notifies quickly the highest linear association between 
metabolite levels and batch of analysis, as calculated based on adjusted coefficient of determination. The imple-
mentation of the “dbnorm” package is publicly available at https ://githu b.com/NBDZ/dbnor m. In this report, we 
applied “dbnorm” to two large-scale metabolomics datasets as a proof of concept. We showed the properties of 
“dbnorm” to help users select the most efficient statistical tool to remove batch effects in metabolomics datasets 
and to thereby detect the relevant biological components of complex metabolomics datasets.
Figure 1.  Monitoring of batch effect in the LC–MS targeted metabolomics analysis of the SKIPOGH human 
cross-sectional study with “dbnorm”. 1079 plasma samples were analyzed in 11 analytical batches over a period 
of 12 months. 239 metabolites were detected. (A) PCA of raw data shows separation of sample clusters mainly 
triggered by batch order. PCAs of lowess-, ber-, nonparametric ComBat-, parametric ComBat-, and bagging ber-
corrected data showed decreased distinction between samples analyzed in the different batches. (B) Adjusted 
Coefficient of Determination (adj-R2), as estimated by regression model. In raw data metabolite intensities were 
strongly associated to batch level, some residual association was observed in lowess- and nonparametric ComBat-
corrected data, while no association was present in parametric ComBat-, ber- and bagging ber-corrected data. 
(C) Score performance calculation for the correction of the signal drift across batches: the maximum absolute 
adj-R2, as estimated by regression model, is calculated for each dataset and presented as a bar plot. The lower the 
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Results
Example analysis 1: batch effect correction in a large-scale targeted metabolomics dataset 
with “dbnorm”. The first dataset on which “dbnorm” was tested is a targeted measurement of the plasma 
metabolome of 1,079 individuals in the human SKIPOGH cohort. These samples were analyzed in 11 analyti-
cal batches over a period of 12 months, together with 135 QC samples that were injected every 10 samples (see 
Methods section). Data were generated in both positive and negative ionization modes, and 239 metabolites 
have been detected across all samples.
Assessment and correction of the batch effect with “dbnorm”. “dbnorm” was first employed to 
perform an explorative statistical analysis of the results obtained in this dataset. The Principal Component 
Analysis (PCA) plot of raw data generated by “dbnorm” showed that the samples were clustered by batch order 
(Fig. 1A). In parallel, the adjusted coefficient of determination (adj-R squared  (R2)) revealed that the variability 
in the dataset was highly dependent on the across-batch signal drift, with > 50% of the variability explained by 
batch for most metabolites (Fig. 1B and Supplementary Table 1).
We thus employed the different statistical models implemented in the “dbnorm” R package to remove the 
batch effect observed in the entire dataset. To assess the efficiency of the “dbnorm” statistical methods, we also 
compared their performance with that of a reference QC sample-based model, such as lowess. PCA plots showed 
the spatial separation predictive of the batch effect, which was significantly reduced after correction of the data 
with all of the tested models (Fig. 1A). By applying all types of correction algorithms, the variability associated 
with each detected feature was strongly reduced, particularly with the two ber models and parametric ComBat 
(Fig. 1B), while with nonparametric ComBat, several metabolites still showed some residual variability. Of note, 
for each statistical model employed, “dbnorm” calculates a score, whose range is between 0 and 1, which is based 
on the highest adjusted-R squared (adj-R2). This simple measure of what percentage of variance (scaled to 100) 
of a dependent variable (i.e., metabolic feature) is explained by an independent variable (i.e., batch) prior to 
and after applying “dbnorm”, allows the user to quickly identify the statistical model that better fits the dataset. 
In addition, based on the proportion of variability explained by batch, “dbnorm” suggests the best compromise 
for correction of batch effects, also considering the consistency of overall model performance for all detected 
metabolites (see the Methods section). As shown in Fig. 1C, in our cohort study, the maximum variability 
detected for a metabolite was 0.78 (78%) for the lowess-corrected dataset (Supplementary Table 2). Similarly, 
for the nonparametric ComBat corrected dataset, a residual maximum variation of 0.60 (60%) was still detected 
(Supplementary Table 5), indicating the remaining signal drift across batches for some metabolites. In contrast, 
the datasets corrected by ber and parametric ComBat functions presented a similar performance in this study, 
with a maximum variability associated with the batch < 0.01 (1%) (Supplementary Tables 3–4). These results 
indicate that both of these functions (i.e., ber and parametric ComBat) are very efficient in normalizing the signal 
intensity changes in this large-scale metabolomics dataset.
One peculiar feature of “dbnorm” is the possibility of easily visualizing the signal distribution of each feature 
individually. Probability density function plots (PDF plots) showing the distribution across the batches of the 
metabolite signal can easily be generated for each metabolite. As an example, PDF plots of 3-hydroxy-3-methyl-
glutarate and 2′,3′-cyclic phosphate 3′-CMP in the SKIPOGH dataset show to what extent each statistical model 
improves the overlapping signal distribution and reduces the variance scale compared to the raw data (Fig. 2A).
For each metabolite, “dbnorm” can also generate violin plots, which further help users to visualize the asso-
ciation of the signal intensity with batch number. Figure 2B shows the clear batch-dependent shift in the signal 
intensity of citrate, which was observed in the raw data and that was still present for some batches in the lowess-
corrected data. In contrast, in the data corrected with each of the “dbnorm” statistical methods, the average 
intensity of this metabolite remained constant across the batches (Fig. 2B). Another interesting observation 
in the SKIPOGH dataset was that the use of the statistical models implemented in “dbnorm” allowed us to 
keep some metabolites, such as xanthosine 5′-monophosphate, which was filtered out with lowess. Xanthosine 
5′-monophosphate is a good example of a low-abundance metabolite, likely present in only one portion of the 
samples and thus below the limit of detection in the QC samples due to the pooling-dilution effect.
“dbnorm” enables efficient downstream differential analysis. To investigate whether the use of 
“dbnorm” for batch correction allows for coherent data interpretation, we next explored the impact of each type 
of correction algorithms on the downstream statistical and metabolic pathway analysis in the SKIPOGH study.
All of the subjects of this prospective cohort study were previously phenotyped for kidney functionality 
and its associated parameters, such as age, sex, and creatinine clearance, as an indicator of renal impairment to 
estimate the severity of a kidney  disease45. In addition, the glomerular filtration rate (GFR), a major surrogate of 
kidney function, was measured on a continuous scale and estimated by the Chronic Kidney Disease Epidemiol-
ogy Collaboration (CKD-EPI, see the Methods section)46,47. We thus took advantage of this clinical information 
to validate the efficiency of “dbnorm” in driving the choice of the best statistical model for batch correction. We 
first evaluated the correlation between creatinine levels, as determined by the targeted LC–MS/MS metabolomics 
experiment and those measured in the clinical laboratory with an enzymatic assay. We looked at five datasets: 
raw data, lowess-, ber- and parametric- and nonparametric ComBat-corrected. As expected, all of the tested batch 
effect correction approaches improved the correlation between the clinically measured creatinine levels and 
those obtained using targeted LC–MS/MS analysis. The correlation coefficient (r) changed from 0.18 (Fisher’s 
z = 0.18 with a 95% interval level (CI), 0.12 to 0.24) observed in the raw data, to 0.5 (Fisher’s z = 0.54 with a 95% 
CI, 0.48 to 0.60) in the lowess-corrected data and up to 0.61 (Fisher’s z = 0.71 with a 95% CI, 0.64 to 0.76) for the 
data corrected by statistical models (Fig. 3A). This observation is indicative of the good performance of “dbnorm” 
statistical models in batch correction.
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Figure 2.  Monitoring of batch effect at feature levels in the LC–MS targeted metabolomics analysis of the SKIPOGH human cross-
sectional study with “dbnorm”. 1079 plasma Samples were analyzed in 11 analytical batches over a period of 12 months. 239 metabolites 
were detected. (A) Probability density function (PDF) plots of 3-Hydroxy-3-methylglutarate and Cytidine 2′,3′-cyclic phosphate across 
different experimental runs showed the shift in the distribution of signals in raw data and its adjustment after data lowess-, ber-, parametric 
ComBat-, and nonparametric ComBat- correction. 3-Hydroxy-3-methylglutarate and Cytidine 2′,3′-cyclic phosphate peaks are detected 
in positive and negative mode of acquisitions, respectively. (B) Violin plots of superposed scatter plots across batches for citrate intensities 
showed the shift of average distribution across-batches in raw data, which was still present in some batches in lowess-adjusted data. This 
shift is corrected by ber, parametric ComBat, and nonparametric ComBat. Dots correspond to the level of citrate in each sample and the 
average citrate level in each batch is defined by boxplot. Two-tailed Student’s t-test was used to calculate the significant changes of citrate 
mean level in different batches compared to the batch 1. *, **, *** and **** indicate p-value < 0.05, < 0.01, < 0.001, < 0.0001, respectively.
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To further confirm the efficiency of “dbnorm”-mediated correction in highlighting relevant biological out-
comes, a multiple regression model was applied to the raw, lowess- and ber-corrected data for 934 participants, 
for which complete metadata were available (see the Methods section). In this model, the CKD-EPI level was 
considered as an outcome of renal failure, and the creatinine level was considered a predictor. The model was 
adjusted by sex and age. As presented in Supplementary Table 6A, in the corrected data, creatinine changes 
across the samples were better predictors of the CKD-EPI changes. In fact, the improved estimation of the known 
association between CKD-EPI and  creatinine48 was revealed by the dramatic decrease in the p-value and effect 
size (i.e., the coefficient) in both the lowess- and ber-corrected data compared to the raw data (Fig. 3B, Supple-
mentary Tables 6A–C). In addition, the analysis of variance confirmed that the integration of creatinine levels 
with sex and age in the regression model improved the prediction across the samples of changes of CKD-EPI 
when using either lowess or ber-corrected data (Supplementary Table 7) (see also the Methods section). These 
observations demonstrate that ber, which was scored by “dbnorm” as the statistical method of choice for the 
SKIPOGH dataset, efficiently corrected for batch effects in this dataset, enabling coherent downstream analyses 
compared to the reference QC method lowess.
Figure 3.  Impact of batch effect correction in LC–MS targeted metabolomics analysis of the SKIPOGH 
study on downstream differential analysis. Pearson correlation between levels of creatinine, as measured in 
clinical tests with those measured in LC–MS metabolomics analysis, before or after batch effect correction 
(A). The correlation increases from 0.18 in the raw data, to 0.5 in the lowess-corrected data, to the maximum 
of 0.61 in the data corrected via statistical models (ber, parametric and nonpararmetic ComBat). *** indicates 
p-value < 0.001. (B) Association of CKD-EPI and metabolite levels fails in detecting significant association 
with creatinine levels in raw data, while this expected association is observed in both lowess- and ber-corrected 
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Example analysis 2: batch effect correction in a large-scale untargeted 
metabolomics dataset
Assessment and correction of the batch effect with “dbnorm”. Untargeted metabolome profiling 
is mostly employed to increase the chance of identifying unexpected discriminant biological signals, as it allows 
for the detection of as many metabolite features as possible from diverse chemical classes, without an a priori 
hypothesis. Due to high levels of noise and redundancy, the use of a robust statistical model for batch effect cor-
rection is even more important in untargeted metabolomics datasets. Here, the aim was to evaluate the efficiency 
of the functions implemented in “dbnorm” for batch effect removal in a second totally independent dataset, 
acquired in a full scan mode in an untargeted high resolution MS.
Briefly, the metabolome profile of two types of adipose tissue, visceral (v-AT) and subcutaneous (sc-AT), was 
measured in mice fed with a high fat diet (HFD) and/or a control diet (ctrl) for 1 or 8 weeks. Overall, 264 samples 
were analyzed, including 32 QCs injected every 8 samples. Data acquisition was performed in three separate 
analytical batches in negative mode, and two batches of continues runs were performed in positive mode. Data 
processing using XCMS software (https ://xcmso nline .scrip ps.edu/), yielded more than 20 thousand m/z values, 
sorted and aligned as the features, defining multiparametric metabolic signatures. In particular, 9900 and 11,156 
features were obtained for the positive and negative modes, respectively (see the Methods section). Herein, to 
better show the effect of signal drift across batches, we only present data acquired in the negative polarity.
Unsupervised multivariate analysis of 11,156 metabolic profiles (i.e., PCA and Hierarchical Cluster Analysis 
(HCA)) performed with “dbnorm” revealed the presence of a strong batch effect, with clustering of samples 
according to batches (Fig. 4A,B). In addition, the adjusted coefficient of variation (adj-R2) estimated by the 
regression model indicated that the variability of certain metabolites could be entirely explained by the signal 
Figure 4.  Monitoring of batch effect in LC–MS untargeted metabolomics and its correction with “dbnorm”. 
(A) PCA plots of mouse fat tissue metabolome acquired for 264 samples in negative polarity showed sample 
separation associated with the experimental runs in raw data and its correction upon correction using ber. (B) 
Dendrogram of raw data confirmed clustering of samples linked to batch number, particularly for batch 1. Upon 
correction using ber-function, data points overlapped without any distinct batch driven grouping of samples in 
dendrograms. The color code indicates the batch number. (C) The score plot represents the maximal absolute 
adj-R2 as estimated in raw data and in ber-, nonparametrice ComBat-, and parametric ComBat-corrected data. 
(D) Volcano plots of raw and ber-corrected data demonstrates the impact of HFD on the list of metabolites 
whose level significantly changes in response to the treatment. The metabolites appearing as significantly 
regulated only in ber-corrected data are depicted as red dots and arrows. Significant criteria of Log2FC > 1.5 and 
adj-p-value < 0.05 are considered to draw a list of metabolites with differential level. (E) Venn diagram showing 
the number of metabolites significantly altered by 8 weeks of HFD in sc-AT metabolome before and after batch 
correction through statistical models (ber, parametric and nonparametric ComBat). Correction with either 
parametric or nonparametric ComBat results in the same list of differentially expressed metabolites.
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intensity drift across batches (Supplementary Fig. 1B). The statistical models implemented in “dbnorm” efficiently 
removed the batch effect, as suggested by the PCA score plot (Fig. 4A, Supplementary Fig. 1A) and HCA dendro-
gram (Fig. 4B), with a reduction in variance for the majority of features (potential metabolites) (Supplementary 
Fig. 1B). Interestingly, the ber-corrected data showed the lowest dependency on the batch level, with a consistent 
effect on all features, as shown by the adj-R2 value near zero. The very low negative adj-R2 values after ber cor-
rection are indicative of a very poorly fitted regression model, demonstrating a weak batch effect dependence 
estimated by the model. The performance of each of the statistical models to correct for batch effect that are 
implemented in “dbnorm” was also visualized by the score plot (Fig. 4C), which confirmed the lowest batch to 
feature dependency in the ber-corrected data.
“dbnorm” enables the discovery of biologically relevant changes. We finally used our untargeted 
metabolomics dataset to further confirm the efficiency of batch effect correction with “dbnorm” to maximize the 
capture of the true biological differences. To simplify the data interpretation and to rapidly identify trends drawn 
from the data analysis, we focused on a subset of data. To this end, we investigated the impact of batch effect 
correction with “dbnorm” on the relative changes induced by 8 weeks of HFD in the metabolome of sc-AT. We 
compared the candidate list obtained from the statistical analysis of raw data to that from the data normalized for 
batch effects using the statistical functions implemented in “dbnorm”. The results showed that while the majority 
of the significant changes were detected in all analyzed datasets, the list of candidate metabolites associated with 
the HFD treatment was more exhaustive after data adjustment. In particular, as depicted in the volcano plots and 
in the Venn diagram (Fig. 4D,E), the levels of several metabolites were significantly affected by HFD only after 
batch effect removal. Interestingly, the majority of these compounds (5 out of 7) belonged to the lipid classes 
(Supplementary Table 8A), which is consistent with the biological effect of HFD on adipose tissue. This result 
suggests that, in this dataset, data correction with the best fitting model proposed by “dbnorm”, in this case ber, 
enables the detection of biological signals induced by HFD that might be relevant but might be overlooked due 
to nonbiological variation between samples.
To further explore the relevance of the additional biological signals highlighted after data correction with 
“dbnorm”, we next annotated the metabolites that were significantly influenced by HFD to functional pathways 
by using metabolite set enrichment analysis (MSEA). We focused only on the ber-corrected data since the list 
of significant metabolites obtained with these data included all of those defined by ComBat-corrected data. 
Interestingly, as shown in Supplementary Fig. 2, some lipid metabolism pathways, such as “alpha-Linolenic acid 
metabolism” and “Fatty acid biosynthesis”, were enriched, as dysregulated functions, only using the list of the 
differential metabolite derived from ber-corrected data (Supplementary Fig. 2). Of note, these two pathways 
were previously shown to be influenced by HFD in adipose  tissue49,50. Few metabolites belonging to these two 
pathways were also identified as significant in the raw data (Supplementary Table 8A), but their numbers were 
not sufficient to trigger an enrichment of the corresponding pathways (Supplementary Table 8B).
Therefore, batch effect removal using the ber function implemented in “dbnorm” improved the data structure 
and enabled us to better capture relevant biological signals in our study in a mouse model of obesity. Collec-
tively, our demonstrative analyses strongly indicated that “dbnorm” is an efficient tool in helping users analyze 
the structure of their data. Moreover, it provides choices among several statistical models that showed good 
performance in metabolomic datasets, as demonstrated by their comparison with a reference QC sample-based 
method for data correction.
Discussion
Metabolic profiling offers holistic determination of intermediate and end products of metabolism whose devia-
tion from normal levels might provide important information on the dysregulation of metabolic pathways in 
disease conditions. Such changes can be caused by genetic disorders, environmental factors, drug treatment, etc. 
This information could help improve disease diagnosis, prognosis and treatment choices. However, population-
based studies need efficient experimental design and data preprocessing to generate comparable sample sets 
across batches.
Our study, in agreement with previous reports, supports the necessity of data cleaning to remove unwanted 
technical variation, which helps improve the detection of biological mechanisms underlying a medical state. 
Rather than highlighting new biological findings associated with phenotypes of the two sets of samples that 
we analyzed here, our study aimed to provide clear-cut evidence that the choice of an appropriate normaliza-
tion model is crucial to remove nonbiological variation to better determine the true biological effect of clinical 
conditions and diet treatments. We provide “dbnorm” as an efficient and user-friendly tool for the removal of 
drift across batches.
Our results show how “dbnorm” helps users diagnose the presence of analytical drift through the genera-
tion of a panel of graphs depicting PCA and distance clustering analysis to assess data structure at the sample 
level, and also scatter, violin and density plots to explore data at the feature level. Moreover, “dbnorm” provides 
choices among several state-of-the-art statistical models, including ComBat (both parametric and nonparametric 
versions) and ber (including its bagging version), whose performance in batch effect correction can be easily 
evaluated through the generation of the same panel of graphs and through the estimation of an adj.  R2 score, 
which notifies the user about the percentage of variance in the corresponding datapoint associated with the batch 
level. Our example analyses clearly show that the statistical models implemented in “dbnorm” can perform an 
accurate correction of batch correction, as demonstrated by their comparison with a reference QC sample-based 
method for data correction.
Periodic injection of QC samples is one of the most commonly used methodologies in the metabolomics com-
munity and is exploited by QC sample-based correction models. However, this methodology has the limitation 
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of being dependent on the availability of QCs truly representative of all of the study samples, whose adequate 
preparation is not always possible, particularly in large-scale studies. If surrogate QC samples are used, QC-based 
normalization methods might fail to remove batch effects homogenously for all of the features characterizing the 
multiparametric metabolic profile. Our results confirm some limits of such correction methods. For instance, we 
showed that in the human dataset that we analyze, citrate levels remained highly associated to the batch order 
in the lowess-adjusted data, which might generate bias in data interpretation. In addition, the analysis with a 
QC sample-based correction model is restricted only to the metabolites that are detected in both the QC and 
the study samples, thus potentially impairing the discovery of novel biological hits in a medical condition. As 
another example, xanthosine 5′-monophosphate was only detected in the study samples but not in the QCs and 
was therefore discarded a priori by the lowess model. In our human population dataset, while variability linked 
to batches is still present for some metabolites by using QC sample-based lowess correction model, all of the 
statistical models implemented in the “dbnorm” package present a higher performance on the overall correc-
tion of the signal drift across batches, with parametric ComBat and ber showing the best score in reducing the 
association between a metabolite feature and the batch level. We cannot exclude that other datasets with a differ-
ent data structure might be more effectively adjusted by nonparametric ComBat and QCsample-based models.
Our results clearly demonstrate the substantive impact of data adjustment for analytical heterogeneity on 
the prediction of clinical outcomes. In the human study, data normalization triggered an increased association 
between eGFR (the outcome measured via the CKD-EPI formula) and creatinine, thus highlighting a pattern 
that was not detected in the raw data. This result indicates that batch effect correction performed on our dataset 
favors the detection of biologically relevant differences. Of note, the ber and ComBat functions have both been 
developed to avoid overfitting of the data in the case of a small sample set in each batch.
In the mouse-model experiment, the statistical models compensating for across-batch signal drift drastically 
decreased the high variability associated with the batch level in the raw dataset to an almost zero level in the 
corrected datasets, with a more consistent removal observed when employing the parametric ComBat model 
and ber model. Data correction resulted in a slightly distinct list of differential features associated with HFD 
treatment, with similar candidates given by functions such as ber, parametric ComBat and nonparametric Com-
Bat. Although the list generated by using the ber function added up to only a few metabolite candidates, these 
metabolites belong to different lipid classes that, in fact, are known to be controlled by HFD. As a consequence, 
this difference increased the enrichment of two biological pathways that are known to be affected by HFD treat-
ment, thus improving the biological significance of the results.
In conclusion, “dbnorm” assists users in visualizing the structure of large metabolomic datasets before and 
after correction via the implemented statistical methods, not only from the perspective of samples analyzed in 
the entire experiment, but also from that of the metabolic features detected in the study samples. Importantly, 
“dbnorm” can also be used for metabolomic studies lacking appropriate QC samples. In the future, “dbnorm” 
and its application could be extended to other high-throughput techniques.
Methods
Package. “dbnorm” and its functions are explained in detail in the Package Manual. Briefly, it includes dis-
tinct functions for pre-processing of data and estimation of missing values, conventional functions for batch 
effect correction based on statistical models, as well as functions using advanced statistical tools to generate 
several diagnosis plots to inform users about their data structure. The “dbnorm” package includes statistical 
tools which allows user to inspect the structure and quality of multidimensional datasets of large metabolomics 
datasets at both macroscopic and microscopic scale, namely at the sample batch level and metabolic feature level, 
respectively. This package is publicly available at https ://githu b.com/NBDZ/dbnor m .
Batch correction models implemented in the “dbnorm” are adapted from microarray analysis, namely, ber 
statistical model, including its bagging variant (ber: https ://cran.r-proje ct.org), and ComBat in both settings of 
parametric and nonparametric from sva package in R (sva; https ://bioco nduct or.org). In brief, ComBat uses EB 
method to remove location (mean) and scale (variance) of batch effect.
In contrast, ber function uses linear regression at two stages to estimate location and /or scales  parameters43.
The bagging variant of ber model uses aggregated prodictors with better accuracy that are obtained from 
bootstrapped predictors. In “dbnorm” we considered a bootstrap sample size of n = 150 and a partial bagging 
procedure.
Human study. SKIPOGH (Swiss Kidney Project on Genes in Hypertension) is a family-based multi-center 
population-based study exploring the role of genes and kidney haemodynamics in blood pressure (BP) regula-
tion and kidney function. Method and population are described in detail  elsewhere51–53. Briefly, in this study 
1079 plasma samples from SKIPOGH population have been considered. For all samples information for gen-
der and age were available, while CKD-EPI levels were only available for 934 samples. The SKIPOGH study 
was approved by the institutional ethical committees of the three participating university hospitals (Lausanne, 
Geneva, Bern) and was performed in accordance with Swiss guidelines and regulations. All study participants 
provided written informed consent.
Animal experimentation. All animal experiments and procedures were approved by the Swiss Veterinary 
Office (VD-2942.b. and VD-3378), were performed in accordance with Swiss guidelines and regulations (OPAn) 
and were carried out in compliance with the ARRIVE guidelines for using animal in studies. C57/BL6 male mice 
were purchased from Janvier Labs and housed 5 per cage in the animal facility of Centre for Integrative Genom-
ics, University of Lausanne.
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Four-week old mice were fed for two weeks with a 10% in fat chow diet (D12450J, Research Diet). At 6 weeks 
of age they were either shifted to a high-fat diet (HFD) containing 60% fat (D12492, Research Diet) or kept on 
a control diet for 1 or 8 weeks. Random blocking was used. Efficiency of the diet-induced obesity was followed 
by regular measurements of  weight54. All animals were kept in a 12:12 h light:dark cycle with water and food 
ad libitum. All the mice were sacrificed by  CO2 between ZT2 and ZT5. In this study sc-AT refers to inguinal 
subcutaneous adipose tissue in mice.
Metabolomics. Targeted metabolomics analysis conducted on the plasma samples of the human prospec-
tive cohort study. Metabolites were extracted from 100 µL samples using a methanol-ethanol solvent mixture 
in a 1:1 ratio. After protein precipitation, supernatant was evaporated to dryness and finally re-suspended to 
100µL  H2O 10% MeOH. The samples were analyzed by LC-MRM/MS on a hybrid triple quadrupole-linear 
ion trap  QqQLIT (Qtrap 5500, Sciex) hyphenated to a LC Dionex Ultimate 3000 (Dionex, Thermo Scientific). 
Analysis were performed in positive and negative electrospray ionization using a TurboV ion source. The MRM/
MS method included 299 and 284 transitions in positive and negative mode respectively, corresponding to 583 
endogenous metabolites. The Mass Spectrometry Metabolite Library (Sigma Aldrich) was used as reference 
material for the standard metabolites.
The chromatographic separation was performed on a column Kinetex C18 (100 × 2.1 mm, 2.6 µm). The mobile 
phases were constituted by A: H2O with 0.1% FA and B: Acetonitrile (ACN) with 0.1% formic acid (FA) for the 
positive mode. In the negative mode, the mobile phases were constituted by A: ammonium fluoride 0.5 mM in 
 H2O and B: ammonium fluoride 0.5 mM in ACN.
The linear gradient program was 0–1.5 min 2%B, 1.5–15 min up to 98%B, 15–17 min held at 98% B, 17.5 min 
down to 2%B at a flow rate of 250 µL/min.
Total 1079 different plasma samples were analyzed in 11 batches over 12 months. 135 and 156 QCs were also 
periodically injected between sample runs in the positive- and negative- modes respectively. Surrogated QCs 
were considered in this study to prevent repeated thawing-refreezing cycles.
The MS instrument was controlled by Analyst software v.1.6.2 (AB Sciex). Peak integration was performed 
with MultiQuant software v.3.0 (AB Sciex). The integration algorithm was MQ4 with a Gaussian smoothing of 
a half-width equal to 1.5 points.
On the other hand, to obtain the fat metabolome profile of mice, metabolites were extracted from 10–20 mg 
of fat depots either sc-AT or v-AT using 400 µL of mix organic solvent comprising EtOH: MeOH:  H2O in the 
proportion of 2:2:1 to remove protein efficiently as well as to extract polar and semi-polar metabolites success-
fully. All the samples were then vortexed mixed for 30 s, incubated for 10 min at 4 °C and centrifuged for 10 min 
at 14,000 rpm and 4 °C. The supernatants were removed and evaporated to dryness using speed vacuum concen-
trator (SpeedVac) and stored at -80 °C until analysis. QCs were prepared by pooling all the tissue integrated in 
the study. Extraction was done using similar protocol use for the samples. Supernatant were aliquots in 34 tubes 
considering similar quantity. Then they were treated like samples.
Untargeted metabolomics approach applied in this study has been described in our previous  papers55,56. 
Briefly, untargeted metabolomics was performed using UPLC (Dionex,Thermo Fisher Scientific) hyphenated 
with HRMS QExactive plus (Thermo ScientificTM Q ExactiveTM). Metabolome profile of fat tissue (i.e. v-AT 
and sc-AT) was obtained for 264 samples including 32 QCs and 232 adipose tissue Samples were injected in two 
batch blocks in a random order. QCs were injected within each batch run regularly (every 7 to 8 samples), to 
assess data quality. HRMS was interfaced with an electrospray ionization (ESI) source operated in both negative 
(NEG) and positive (POS) polarities. Data acquisition in POS mode has been finalized in two days of continues 
run, while NEG mode was completed in three separated analytical runs. ESI source was optimized using sheath 
gas flow rate 40, auxiliary gas flow rate 10, capillary temperature 320 °C, S-lens RF 50 and auxiliary gas heater 
temperature 300 °C. All the ESI parameters were identical in both ionization modes except the sweep voltage 
which was selected to have proper spray current (for POS 3.3 kV and for NEG 2.9 kV). Moreover, lock mass was 
considered with respect to the acquisition mode which permit real-time recalibration by correcting m/z shifts 
compensating for the instrumental drift. UPLC was performed on a C18 Kinetex, 2.6 μm, 50 mm × 2.1 mm I.D. 
column (Phenomenex, PA) in Reverse Phase chromatography. Mobile phase was composed of A = 0.1% Formic 
acid in H2O and B = 0.1% Formic acid in MeOH for both positive and negative ionization modes. Elution was 
carried out in gradient condition and mobile phase composition changed from 98% A (0–6 min) to 100% B 
(6.1–9 min) and stabilized for 4 min for column re-equilibrating likewise to keep analysis reproducibility. The 
overall run time was 13 min. Flow rate was set at 0.3 mL/min and the sample injection volume were 2.5μL count-
ing for half loop portion. Identity of interested features confirmed mainly using a targeted selected ion monitor-
ing (tSIM) data dependent MS/MS acquisition method (tSIM/ddMS/MS). In tSIM/ddMS/MS, the precursors 
enlisted in the inclusion list were selected in the quadrupole with 2 Da isolation width, followed by a ddMS/MS 
scan with the similar isolation window. The number of precursor scans for co-eluting analytes (MSX) was set 
at 1. The precursor ions were selected using loop count = 5, MSX = 1 and MS/MS spectra acquired simultane-
ously for 5 ions within the isolation windows at each scan. Resolutions were set at 70,000 and 17,000 for tSIM 
and ddMS/MS respectively. The AGC targets for tSIM were set at 2 × 105 with the maximum inject time (IT) of 
150 ms and for ddMS/MS at 1 × 105 with IT = 100 ms. MS/MS spectra were generated when the signal reaches 
the threshold of 1%.
Yet, some interesting metabolic features were notified as semi-identified, that means they are identified as a 
potential meknown metabolite based on their accurate mass, real peak shape and retention time.
Raw data were then transformed to mzXML format using MSConvert (Proteo Wizard 3.07155) and pre-pro-
cessed for peak peaking, chromatogram alignment and isotope annotation using open access XCMS online (https 
://xcmso nline .scrip ps.edu). XCMS runs on UPLC-QExactive parameters by setting peak detection on Centwave.
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Chemometrics and Pathway analysis. For analysis, raw data generated in the targeted metabolomics 
were log2-transformed for each metabolite. Further normalization for across-batch signal drift was done using 
either QC-based model specifically lowess-model from open access web page (http://prime .psc.riken .jp/Metab 
olomi cs_Softw are/LOWES S-Norma lizat ion/) or non-QC based algorithms using “dbnorm” package. Notably, 
data for each mode of acquisition was treated separately for batch effect removal through either of QC-based 
or non-QC-based model, and then merged for visual check and downstream differential analysis. A total of 
239 different plasma metabolites detected in a human prospective cohort study among which XANTHOSINE 
5′-MONOPHOSPHATE was missing in QCs analyzed in positive modes.
Untargeted metabolomics data subjected to batch effect was also treated for normalization of a cross- batch 
signal drift using statistical methods implemented in the “dbnorm” package, which is also used for visualization 
of the outcome. In fact, in this study, the major focus is given to negative polarity in which data acquisition were 
completed in three separated analytical runs and thereby typically subjected to batch effects.
Metabolome signature in either of study, human study and animal experiment, was obtained by linear logistic 
regression model using lm (R Stats Package) and limma package (https ://bioco nduct or.org), respectively.
In the human cohort study, even though metabolomics analysis and data processing has been performed on 
all 1079 samples, evaluation of differential biological effect performed on 943 participants for which information 
on CKD-EPI level were available. GFR is estimated by an equation developed by the Chronic Kidney Disease Epi-
demiology Collaboration (CKD-EPI) used as an outcome of renal impairment. CKD-EPI as estimator of kidney 
function calculated by gender and stratified by creatinine is assessed via formula presented in the  reference57.
Pearson’s r is calculated to rigorously estimate relationship between creatinine level measured in clinical rou-
tine and by MS. CIs at α < 0.05 (i.e. at 95% level) were produced upon transformation of pearson’s r to fisher’s z.
Subsequently, the association between CKD-EPI and plasma metabolome were investigated by multiple 
regression testing adjusted for age and sex. Bonferroni corrected p-value was considered as the significant cri-
terion for the metabolite selection.
Then, volcano plot was used to visualize significance and the magnitude of changes in metabolites associated 
with CKD-EPI level.
In mouse model of obesity, we mainly focused on sc-AT metabolome signature driven by HFD after 8 weeks 
treatment, in comparison with their control counterpart. Linear regression model was used and significant cri-
teria for metabolite selection were set at Log2FC > 1.5 and benjamini and bochberg (BH) adjusted p-value < 0.05.
Subsequently, significant list was further searched and filtered against a Human Metabolome Database 
(HMDB; http://www.hmdb.ca) to keep only potential hits that were ultimately either partially confirmed based 
on peak shape and retention time denoted as “semi” or fully confirmed based on MS/MS spectra.
Differential list associated with 8 weeks of HFD treatment was then subjected to over-representation analysis 
(ORA) using web interface of ConsensusPathDB ( http://conse nsusp athdb .org/) to pinpoint biochemical path-
ways that are dysregulated and may have a causative relationship to the phenotype. The list of identifiers was 
mapped to predefined KEGG pathways database enlisted by 4289 compound IDs. As defined by software, “p-value 
is calculated according to the hypergeometric test based on the number of physical entities present in both the 
predefined set and user-specified list of physical entities” (http://cpdb.molge n.mpg.de/). Result includes q-value 
which is in fact the p-values corrected for multiple testing using the false discovery rate. The selection criteria 
for a significantly dysregulated biological function was set to at least two metabolites representing the biological 
pathways with q-value < 0.05. Significant pathways were visualized ed using bar plot. In this plot, primary y-axis 
notifies Metabolite’s coverage, calculated as relative number of input metabolite define a pathway to a whole 
metabolite set of a pathway. Secondary y-axis presents q-value defined for each pathway in negative log2 scale.
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